Key Takeaways
- • Garrett Smith, UC San Diego bioengineering PhD ('12) with experience across founder, operator, corporate innovation, and venture roles, has launched ReefHaven Ventures as a San Diego-focused early-stage medical technology venture capital fund.
- • ReefHaven Ventures has already deployed capital into three UC San Diego-affiliated medtech companies—KatoMed, Acurion, and Dragon Vascular—with plans for more than two dozen additional San Diego medtech investments over the coming years.
- • The fund targets startups at the convergence of medical technology, artificial intelligence, and robotics, addressing what Smith identifies as a gap in early-stage investor support in San Diego's innovation ecosystem relative to the Bay Area.
- • Smith's operational track record includes steering multiple technologies through FDA approval, leading startups to successful acquisition, directing innovation partnerships for Johnson & Johnson Innovation, and overseeing a corporate venture capital fund at MedeonBIO.
- • UC San Diego consistently ranks in the top 10 universities nationally for startup creation, providing a robust pipeline of early-stage opportunities for ReefHaven's investment thesis.
Summary
Garrett Smith has established ReefHaven Ventures as a San Diego-based venture capital fund dedicated to early-stage medical technology startups, leveraging over a decade of experience across the healthcare innovation ecosystem. Smith founded his first company while completing his bioengineering PhD at UC San Diego in 2012 and has since accumulated substantial operational and investment experience, including roles as a founder, corporate innovation leader at Johnson & Johnson Innovation, and fund manager at MedeonBIO.
The fund addresses a structural gap Smith has identified in San Diego's startup ecosystem. While UC San Diego ranks consistently among the top 10 universities nationally for startup creation, the region lacks the depth of early-stage investor support available in established venture hubs like the Bay Area. ReefHaven's mandate is to reinvest capital directly back into the local innovation ecosystem, anchoring its strategy around San Diego-based founders and technologies.
ReefHaven has initiated its investment activity with three portfolio companies sourced from UC San Diego's innovation pipeline: KatoMed, Acurion, and Dragon Vascular. These initial investments reflect the fund's strategic focus on the intersection of medical technology, artificial intelligence, and robotics. The firm projects deploying capital into more than two dozen additional San Diego medtech companies over the next several years, establishing a concentrated geographic and thematic investment thesis.
Paul Roben, Associate Vice Chancellor for Innovation and Commercialization at UC San Diego, highlighted the university's track record as a source of venture-quality technologies, underscoring the institutional support for Smith's fund thesis. The combination of Smith's operational credibility—including demonstrated success navigating FDA approval pathways and executing acquisitions—and ReefHaven's focus on an underserved early-stage segment positions the fund to capture deal flow at a critical stage of company development when capital and operational guidance from experienced medtech leaders carry material impact.
The fund addresses a structural gap Smith has identified in San Diego's startup ecosystem. While UC San Diego ranks consistently among the top 10 universities nationally for startup creation, the region lacks the depth of early-stage investor support available in established venture hubs like the Bay Area. ReefHaven's mandate is to reinvest capital directly back into the local innovation ecosystem, anchoring its strategy around San Diego-based founders and technologies.
ReefHaven has initiated its investment activity with three portfolio companies sourced from UC San Diego's innovation pipeline: KatoMed, Acurion, and Dragon Vascular. These initial investments reflect the fund's strategic focus on the intersection of medical technology, artificial intelligence, and robotics. The firm projects deploying capital into more than two dozen additional San Diego medtech companies over the next several years, establishing a concentrated geographic and thematic investment thesis.
Paul Roben, Associate Vice Chancellor for Innovation and Commercialization at UC San Diego, highlighted the university's track record as a source of venture-quality technologies, underscoring the institutional support for Smith's fund thesis. The combination of Smith's operational credibility—including demonstrated success navigating FDA approval pathways and executing acquisitions—and ReefHaven's focus on an underserved early-stage segment positions the fund to capture deal flow at a critical stage of company development when capital and operational guidance from experienced medtech leaders carry material impact.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.